Celgene Corporation (CELGZ) was a publicly-traded biopharmaceutical company that focused on the discovery, development, and commercialization of drugs for the treatment of cancer and other diseases. The company was founded in 1986 and was headquartered in Summit, New Jersey.
However, as of 2019, CELGZ was acquired by Bristol-Myers Squibb Company and is no longer a publicly-traded company. Prior to the acquisition, the company had a strong pipeline of drug candidates in development for various indications, including multiple myeloma, pancreatic cancer, and psoriasis.
CELGZ had a strong reputation in the industry and was recognized for its innovative research and development programs. The company had established partnerships with various research institutions and biopharmaceutical companies to further its drug development programs.
Investing in biopharmaceutical companies like CELGZ carries certain risks, including the potential for market fluctuations, regulatory risks, and clinical trial risks. Additionally, the success of a company's therapies is dependent on several factors, including the safety and efficacy of the products and the ability to obtain regulatory approval. Potential investors should carefully consider these risks before making any investment decisions.
|
